Patents Issued in July 9, 2020
  • Publication number: 20200216439
    Abstract: Compounds of formula (I) as described herein, processes for their production and their use as pharmaceuticals.
    Type: Application
    Filed: December 12, 2016
    Publication date: July 9, 2020
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Keith GRAHAM, Ulrich KLAR, Hans BRIEM, Gerhard SIEMEISTER, Ursula MÖNNING, Franz VON NUSSBAUM
  • Publication number: 20200216440
    Abstract: The present invention provides a compound, that is a 1-({halo-2-[(2-hydrocarbyl or substituted hydrocarbyl)oxy]phenyl}methyl)-(fused bicyclic nitrogen heteroaryl) carboxylic acid or an ester or sulfonamide thereof. The compound may be represented by the following formula Wherein R1, R2, R3, R4 A, X, W, Z and Y are as defined in the specification. The compounds may be administered to treat DP, FP, EP1, TP and/or EP4 receptor-mediated diseases or conditions.
    Type: Application
    Filed: August 13, 2019
    Publication date: July 9, 2020
    Inventors: William R. Carling, Jose L. Martos, Jussi J. Kangasmetsa, Jenny W. Wang, David F. Woodward
  • Publication number: 20200216441
    Abstract: Compounds of formula I (I), wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides and can be prepared in a manner known per se.
    Type: Application
    Filed: April 19, 2018
    Publication date: July 9, 2020
    Applicant: SYNGENTA PARTICIPATIONS AG
    Inventors: Sebastian RENDLER, Andrew EDMUNDS, Daniel EMERY, Pierre Joseph Marcel JUNG, Michel MUEHLEBACH, Girish RAWAL, Indira SEN, Vikas SIKERVAR
  • Publication number: 20200216442
    Abstract: An N-benzenesulfonylbenzamide compound represented by the formula (I), or a crystal form, a prodrug, pharmaceutically acceptable salts, a stereoisomer, a solvate or a hydrate thereof, a pharmaceutical composition containing same, and a use thereof as a Bcl-2 protein inhibitor for preparing a medicament for treatment of leukemia or a cancer.
    Type: Application
    Filed: June 25, 2018
    Publication date: July 9, 2020
    Inventors: Yihan Wang, Zhiqiang Liu
  • Publication number: 20200216443
    Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (I) Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Application
    Filed: July 30, 2018
    Publication date: July 9, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Hua Zhou, Abdelghani Achab, Xavier Fradera, Yongxin Han, Derun Li, Meredeth A. McGowan, Nunzio Sciammetta, David L. Sloman, Wensheng Yu
  • Publication number: 20200216444
    Abstract: The present invention provides a new crystal form of a N-phenyl-2-aminopyrimidine compound, a crystal form of a pharmaceutically acceptable salt of said compound, and a preparation method for these crystal forms and use thereof. The present invention also relates to a pharmaceutical composition and a pharmaceutical preparation comprising the crystal form of said compound and the crystal form of the pharmaceutically acceptable salt of said compound, and use of these crystal forms, the pharmaceutical composition and the pharmaceutical preparation for treating diseases or conditions associated with the cell epidermal growth factor receptor (EGFR), for example, for treating or improving abnormal cell proliferative conditions, such as cancer.
    Type: Application
    Filed: June 29, 2018
    Publication date: July 9, 2020
    Applicant: HAINAN YUEKANG BIOMEDICINES CO., LTD.
    Inventor: Maosheng DUAN
  • Publication number: 20200216445
    Abstract: The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains, and methods of synthesis of these compounds.
    Type: Application
    Filed: September 14, 2018
    Publication date: July 9, 2020
    Inventors: Shawn E.R. Schiller, Torsten Herbertz, Hongbin Li, Bradford Graves, Steven Mischke, Angela V. West, Jennifer R. Downing, Anna Ericsson
  • Publication number: 20200216446
    Abstract: The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure useful for the synthesis of compounds that target KRAS G12C mutations, such as
    Type: Application
    Filed: November 15, 2019
    Publication date: July 9, 2020
    Inventors: Andrew Thomas PARSONS, Brian McNeil COCHRAN, William POWAZINIK, IV, Marc Anthony CAPORINI
  • Publication number: 20200216447
    Abstract: The invention provides compounds of formula (I): which contain a 4-membered heterocyclic amide, where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: December 3, 2019
    Publication date: July 9, 2020
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: PAUL R. FATHEREE, GARY E.L. BRANDT, CAMERON SMITH, STEVEN D.E. SULLIVAN, LORI JEAN VAN ORDEN
  • Publication number: 20200216448
    Abstract: The present invention relates generally to glutaminase inhibitors of Formula I, Formula II, or Formula III, as well as pharmaceutical compounds containing them and methods of their use.
    Type: Application
    Filed: January 6, 2020
    Publication date: July 9, 2020
    Inventors: Richard CERIONE, Kristin CERIONE, Clint STALNECKER, Scott ULRICH
  • Publication number: 20200216449
    Abstract: Disclosed are a 4-sulfur substituted podophyllotoxin derivative and a synthetic method therefor and the use thereof. In the present invention, introducing heteroaromatic compounds with rigidity, such as 4-trifluoromethylpyridin-2-thiol, 4-trifluoromethyl-2-mercaptopyrimidine, and para-fluorothiophenol, respectively as substituent groups to position 4 of C ring of a podophyllotoxin or 4?-demethylepipodophyllotoxin, obtaining a podophyllotoxin derivative as shown in formula (V) with a significantly improved antitumour activity and reduced toxic side effects. Experiments of in vitro tumour cell activity inhibition indicate that the antitumour activity of the compound as shown in formula (V) of the present invention is significantly improved compared to that of the podophyllotoxin or 4?-demethylepipodophyllotoxin.
    Type: Application
    Filed: March 16, 2020
    Publication date: July 9, 2020
    Inventor: Yajie Tang
  • Publication number: 20200216450
    Abstract: The present invention provides is a compound for inhibiting and degrading CDK. Specifically the present invention provides a compound represented by formula I, definitions of radical groups being described in the specification. The compound in the present invention has a very good inhibitory activity for the cyclin-dependent kinase (CDK), and can be used in the preparation of drugs for treating diseases related to the activity of the CDK.
    Type: Application
    Filed: March 17, 2020
    Publication date: July 9, 2020
    Inventor: Yongzhi SHU
  • Publication number: 20200216451
    Abstract: In some embodiments, provided herein are processes for preparing a compound of Formula C or a salt thereof, as disclosed herein. In some embodiments, provided herein is a compound of Formula I or a pharmaceutically acceptable salt, solvate or hydrate thereof. In some embodiments, provided herein is a solid form of the compound, such as a crystalline form of the compound crystalline Form I.
    Type: Application
    Filed: October 26, 2017
    Publication date: July 9, 2020
    Inventors: Qian Zhao, Stacey Spencer, Yutong Jiang, Julia Haas, Charles Todd Eary
  • Publication number: 20200216452
    Abstract: Described herein are compounds that may selectively bind to Hsp90, methods of using the compounds, and kits including the compounds. The compounds may include detection moieties such as fluorophores that may allow for selective detection of Hsp90 in a sample.
    Type: Application
    Filed: August 26, 2019
    Publication date: July 9, 2020
    Inventors: Timothy Haystead, Philip Floyd Hughes
  • Publication number: 20200216453
    Abstract: The invention relates to stable, isotopically labeled variants of methotrexate for use in mass spectrometry analysis for quantifying methotrexate in a sample. The compounds have the structure wherein each of Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y10, Y11<Y12-Y13 and Y14 is independently selected from carbon or carbon-13; and wherein at least 5 of Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y10, Y11, Y12, Y13 and Y14 are carbon-13.
    Type: Application
    Filed: June 5, 2017
    Publication date: July 9, 2020
    Applicant: Micromass UK Limited
    Inventors: Donald Peter Cooper, Billy J. Molloy
  • Publication number: 20200216454
    Abstract: The invention provides bifunctional compounds which act as protein degradation inducing moieties for a HER family protein, such as Her3. The invention also provides methods for the targeted degradation of a HER family protein through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to the HER family protein which can be utilized in the treatment of disorders modulated by a HER family protein.
    Type: Application
    Filed: December 29, 2016
    Publication date: July 9, 2020
    Inventors: Nathanael S. GRAY, James BRADNER, Pasi JANNE, Jaebong JANG, Dennis BUCKLEY, Dennis DOBROVOLSKY
  • Publication number: 20200216455
    Abstract: The present invention relates generally to proteasome inhibiting ?-lactam compounds useful for the treatment of cancer and neurodegenerative disorders. The invention also provides pharmaceutical compositions and extended release formulations of said compounds, and medical uses of said compounds and/or pharmaceutical compositions to treat cancer and neurodegenerative disorders.
    Type: Application
    Filed: December 22, 2017
    Publication date: July 9, 2020
    Applicants: Vita Api, Etat Français Représenté Par le Directeur Central du Service de Santé des Armées, Université D'Aix-Marseille, Centre National de la Recherche Scientifique
    Inventors: Philippe Yves-Rémy Simon, Henri Oreal, Gérard Audran, Marvin Schulz, Jean-Patrick Joly, Didier Siri, Anouk Siri
  • Publication number: 20200216456
    Abstract: Presently provided are inhibitors of TD02 and IDOl and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2,3 dioxygenase and indoleamine 2,3-dioxygenase 1; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.
    Type: Application
    Filed: June 28, 2018
    Publication date: July 9, 2020
    Inventors: Zhonghua Pei, Brendan Parr, Wendy Liu, Richard Pastor, Lewis Gazzard, Firoz Jaipuri, Sanjeev Kumar, Hima Potturi, Guoshen Wu, Xingyu Lin, Yanyan Chu, Powai Yuen
  • Publication number: 20200216457
    Abstract: Compounds of formula (I) wherein R1, R2, A, W, m, n, p and q are as described herein, compositions including the compounds and methods of using the compounds as autotaxin inhibitors.
    Type: Application
    Filed: March 23, 2020
    Publication date: July 9, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Patrick DI GIORGIO, Jerome HERT, Daniel HUNZIKER, Holger KUEHNE, Patrizio MATTEI, Markus RUDOLPH
  • Publication number: 20200216458
    Abstract: Non-peptide MOR opioid receptor modulators are provided. The compounds exhibit predominantly central activity and are used to treat e.g. substance use disorders, and pain.
    Type: Application
    Filed: December 24, 2019
    Publication date: July 9, 2020
    Inventor: Yan Zhang
  • Publication number: 20200216459
    Abstract: Described herein are certain crystalline forms of Compound 3, as well as pharmaceutical compositions employing the crystalline forms. Also provided are particles (e.g., nanoparticles) comprising such crystalline forms or pharmaceutical compositions. In certain examples, the particles are mucus penetrating particles (MPPs). The present invention further relates to methods of treating or preventing diseases using crystalline forms or pharmaceutical compositions.
    Type: Application
    Filed: March 2, 2020
    Publication date: July 9, 2020
    Inventors: Elizabeth Enlow, Minh Ngoc Nguyen, Winston Z. Ong
  • Publication number: 20200216460
    Abstract: Described herein are crystalline forms of Compound 1 useful for the prevention and treatment of angiogenic ocular conditions; methods of treating a disease comprising; processes for preparing; and kits comprising, the same.
    Type: Application
    Filed: March 13, 2020
    Publication date: July 9, 2020
    Inventors: Minh Ngoc Nguyen, Winston Zapanta Ong
  • Publication number: 20200216461
    Abstract: The present invention relates to the compound of formula (I) wherein R1A, R1B, R1C, and R1D are hydrogen atom, etc., R2A and R2B are hydrogen atom, etc., R3A, R3B, R3C, and R3D are hydrogen atom, etc., L is bond, etc., V is C1-6 alkylene, Q is optionally-substituted imidazole, or a pharmaceutically acceptable salt thereof, as a novel anti-tumor agent that targets CSCs which are thought to be closely involved in the persistent proliferation of malignant tumor, metastasis or recurrence of cancer, and resistance to anti-tumor agents.
    Type: Application
    Filed: March 3, 2020
    Publication date: July 9, 2020
    Applicant: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Hitoshi BAN, Seiji KAMIOKA, Yusuke SAWAYAMA, Miki HASHIZUME
  • Publication number: 20200216462
    Abstract: Disclosed are a 4-sulfur substituted podophyllotoxin derivative and a synthetic method therefor and the use thereof. In the present invention, introducing heteroaromatic compounds with rigidity, such as 4-trifluoromethylpyridin-2-thiol, 4-trifluoromethyl-2-mercaptopyrimidine, and para-fluorothiophenol, respectively as substituent groups to position 4 of C ring of a podophyllotoxin or 4demethylepipodophyllotoxin, obtaining a podophyllotoxin derivative as shown in formula (V) with a significantly improved antitumour activity and reduced toxic side effects. Experiments of in vitro tumour cell activity inhibition indicate that the antitumour activity of the compound as shown in formula (V) of the present invention is significantly improved compared to that of the podophyllotoxin or 4demethylepipodophyllotoxin.
    Type: Application
    Filed: March 20, 2020
    Publication date: July 9, 2020
    Inventor: Yajie Tang
  • Publication number: 20200216463
    Abstract: The invention provides novel cytotoxic compounds and cytotoxic conjugates comprising these cytotoxic compounds and cell-binding agents. More specifically, this invention relates to novel thailanstatin A analogs, useful as cytotoxic small molecule toxins in antibody-drug conjugates (ADCs). The present invention further relates to compositions including these cytotoxic compounds and ADCs, and methods for using these toxins and ADCs to treat pathological conditions including cancer.
    Type: Application
    Filed: September 19, 2018
    Publication date: July 9, 2020
    Applicant: pH Pharma Co., Ltd.
    Inventors: Vasu JAMMALAMADAKA, Kimberly Ann TIPTON, Sanjeev SATYAL, Hoyoung HUH
  • Publication number: 20200216464
    Abstract: The present invention relates to a compound of formula (I) as defined in the description and in the claims. The compound of formula (I) can be used in the manufacture of medicaments.
    Type: Application
    Filed: March 13, 2020
    Publication date: July 9, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Paul SPURR, Roland AGRA
  • Publication number: 20200216465
    Abstract: The present invention relates to certain diaryl macrocyclic compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating cancer, pain, neurological diseases, autoimmune diseases, and inflammation.
    Type: Application
    Filed: February 21, 2020
    Publication date: July 9, 2020
    Inventors: Jingrong Jean Cui, Yishan Li, Evan W. Rogers, Dayong Zhai
  • Publication number: 20200216466
    Abstract: In its many embodiments, the present invention provides certain C5-C6-oxacyclic fused iminothiazine dioxide compounds bearing an ether linker, including compounds Formula (I): or a tautomer thereof, and pharmaceutically acceptable salts of said compounds and said tautomers, wherein R1, R2, R3, RA, ring A, m, n, -L1-, ring B, RB, and p are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.
    Type: Application
    Filed: March 17, 2020
    Publication date: July 9, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Wen-Lian Wu, Jared N. Cumming, Brandon M. Taoka, Xing Dai
  • Publication number: 20200216467
    Abstract: The present invention relates to compounds of Formula (I) inhibiting indoleamine 2,3-dioxygenase (IDO) and/or tryptophan 2,3-dioxygenase (TDO) enzymes. Further, their synthesis and their use as medicaments in inter alia cancer is disclosed.
    Type: Application
    Filed: August 16, 2018
    Publication date: July 9, 2020
    Inventors: Christoph BOSS, Daniel BUR, Sylvaine CREN, Thierry KIMMERLIN, Carina LOTZ-JENNE, Julien POTHIER, Naomi TIDTEN-LUKSCH
  • Publication number: 20200216468
    Abstract: Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using heterocycle amines. Some of the disclosed embodiments include heterocycle amines useful to treat inflammatory disorders.
    Type: Application
    Filed: January 7, 2020
    Publication date: July 9, 2020
    Inventors: Koc-Kan Ho, David Diller, Jeffrey J. Letourneau, Brian F. McGuinness, Andrew G. Cole, David Rosen, Cornelis A. van Oeveren, Jason C. Pickens, Lin Zhi, Yixing Shen, Bijan Pedram
  • Publication number: 20200216469
    Abstract: The present application discloses compounds which are activators of autophagic flux and pharmaceutical compositions comprising said activators. It further discloses use of said compounds and pharmaceutical compositions in the treatment of neurodegenerative diseases, particularly proteinopathies and tauopathies such as Alzheimer's disease. It further discloses methods of enhancing autophagic flux.
    Type: Application
    Filed: March 13, 2020
    Publication date: July 9, 2020
    Inventors: Kirsten Alison Rinderspacher, Wai Yu, Karen Duff, Donald Landry, Shi-Xian Deng
  • Publication number: 20200216470
    Abstract: The present invention provides processes for preparing 7H-pyrrolo[2,3-d]pyrimidine derivatives, which are useful as a Janus kinase (JAK) inhibitor, intermediates thereof, and processes for preparing the intermediates. The present invention provides processes for preparing 3-[(3S, 4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile using salts of (3S,4R)-1-benzyl-3-methyl-1,6-diazaspiro[3.4]octane with organic acids.
    Type: Application
    Filed: December 20, 2017
    Publication date: July 9, 2020
    Inventors: Hiromu Takiguchi, Akinobu Higashi, Takashi Inaba, Takashi Watanabe, Tsubasa Takeichi, Anders Klarskov Petersen, Per Vedsoe, Kim Lebek Jensen, Jan Bornholdt, Soren Ebdrup
  • Publication number: 20200216471
    Abstract: The present disclosure provides methods of inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The methods are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin. Compositions for use in these methods are also provided.
    Type: Application
    Filed: September 19, 2018
    Publication date: July 9, 2020
    Inventors: Tao WU, Liansheng LI, Pingda REN
  • Publication number: 20200216472
    Abstract: The present invention relates to a process for the preparation of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives useful as pharmaceutically active compounds.
    Type: Application
    Filed: March 19, 2020
    Publication date: July 9, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Jean-Michel Adam, Serena Maria Fantasia, Daniel Vincent Fishlock, Fabienne Hoffmann-Emery, Gerard Moine, Christophe Pfleger, Christian Moessner
  • Publication number: 20200216473
    Abstract: The present disclosure relates gold carbene naphthoquinone compounds and salts thereof. In some aspects, these compounds can be used to treat cancer including cancers which are resistant to one or more other chemotherapeutic agents such as cisplatin or platinum chemotherapeutic agents. Also provided herein are pharmaceutical compositions comprising the gold carbene naphthoquinone compounds.
    Type: Application
    Filed: June 29, 2018
    Publication date: July 9, 2020
    Inventors: Jonathan ARAMBULA, Kuppuswamy ARUMUGAM, Jonathan L. SESSLER, Christopher BIELAWSKI
  • Publication number: 20200216474
    Abstract: The use of zinc ketoiminate complexes in the production of polyurethanes is described, wherein the zinc ketoiminate complexes are obtainable by reacting a zinc compound with certain ketimines.
    Type: Application
    Filed: September 14, 2018
    Publication date: July 9, 2020
    Applicant: Evonik Operations GmbH
    Inventors: Michael Fiedel, Thomas Günther, Martin Glos, Michael Ferenz, Christian Eilbracht, Wilfried Knott, Stephan Schulz, Dennis Dittrich
  • Publication number: 20200216475
    Abstract: Provided are a compound of Chemical Formula 1: wherein X1 to X4 are identical to or different from one another and are each independently O, S, NR2 or CR3R4, and a to d are each 0 or 1, with the proviso that 1?a+b+c+d; R1 and R11 to R14 are identical to or different from one another and are each independently hydrogen, deuterium, a nitrile group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group; e is an integer of 0 to 3, wherein, when e is 2 or more, each R1 is identical to or different from each other; aa, bb, cc and dd are each an integer of 0 to 4, wherein, when aa, bb, cc and dd are 2 or more, the substituents in parentheses are identical to or different from one another; R2 is a substituted or unsubstituted aryl group or a substituted or unsubstituted heterocyclic group; and R3 and R4 are identical to or different from each other and are each independently a s
    Type: Application
    Filed: December 26, 2018
    Publication date: July 9, 2020
    Inventors: Hongsik YOON, Yujin KANG, Wanpyo HONG, Sang Duk SUH
  • Publication number: 20200216476
    Abstract: The disclosure includes high purity compounds having CCR5 and/or CCR2 antagonism, or a salt thereof, and processes for synthesizing the same.
    Type: Application
    Filed: January 3, 2020
    Publication date: July 9, 2020
    Inventor: Nicholas Morra
  • Publication number: 20200216477
    Abstract: A method for manufacturing an amino group-containing organosilicon compound of the following formula (1): wherein each R1 independently represents an alkyl group having 1 to 10 carbon atoms, etc., each of R2 and R3 represents a functional group of the following formula (4), etc., m represents an integer of 1 to 3, and n represents an integer of 1 to 12, wherein an asterisk * represents a bond with an adjacent atom, p represents an integer of 1 to 12, and q represents an integer of 1 to 10, the method comprising: (A) reacting an amine compound of the following formula (2): wherein R2 and R3 mean the same as above with a halogen group-containing organosilicon compound of the following formula (3): wherein X represents a chlorine atom, etc., and R1 and n mean the same as above; (B) removing an amine hydrohalide produced in the step (A), by liquid-liquid separation; and (C) neutralizing an organic layer obtained in the step (B), using a base which amounts 0.1 to 0.
    Type: Application
    Filed: December 18, 2019
    Publication date: July 9, 2020
    Applicant: Shin-Etsu Chemical Co., Ltd.
    Inventor: Munenao HIROKAMI
  • Publication number: 20200216478
    Abstract: To provide an electrochromic compound, represented by the following general formula (I): where X1, X2, X3, X4, X5, X6, X7 and X8 are each independently a hydrogen atom or a monovalent substituent; R1 and R2 are each independently a monovalent substituent; A? and B? are each independently a monovalent anion; and Y is represented by the following general formula (II) or (III): where X9, X10, X11, X12, X13, X14, X15, X16, X17, and X18 are each independently a hydrogen atom or a monovalent substituent.
    Type: Application
    Filed: March 16, 2020
    Publication date: July 9, 2020
    Inventors: Toshiya SAGISAKA, Hiroyuki TAKAHASHI, Takashi OKADA, Shigenobu HIRANO, Tohru YASHIRO, Koh FUJIMURA, Yoshihisa NAIJO, Yoshinori OKADA, Kazuaki TSUJI, Sukchan KIM, Keiichiroh YUTANI, Tamotsu HORIUCHI, Mamiko INOUE
  • Publication number: 20200216479
    Abstract: The present invention provides a tungsten compound represented by the following general formula (1): (in the formula, X represents a halogen atom, R1 to R5 each independently represent a hydrogen atom or an alkyl group having 1 to 5 carbon atoms, R6 represents a tertiary butyl group or a tertiary pentyl group, and R7 represents an alkyl group having 1 to 5 carbon atoms. However, when R1 to R5 are all hydrogen atoms and R6 is a tertiary butyl group, and when R1 to R5 are all methyl groups and R6 is a tertiary butyl group, R7 represents an alkyl group having 1 to 3 or 5 carbon atoms).
    Type: Application
    Filed: July 4, 2018
    Publication date: July 9, 2020
    Applicant: ADEKA CORPORATION
    Inventors: Akio SAITO, Tsubasa SHIRATORI, Yutaro AOKI
  • Publication number: 20200216480
    Abstract: A light emitting device having excellent luminance life contains an anode, a cathode, and two organic layers disposed between them. The first layer contains a phosphorescent compound having formula (1) and a compound having formula (H), and the second layer contains a crosslinked body of a crosslinkable material. M represents Ir, n1 represents an integer of 1 or more, n2 represents an integer of 0 or more, E1 and E2 each represent a carbon atom, ring L1 represents an aromatic heterocyclic ring, ring L2 represents an aromatic hydrocarbon ring, and A1-G1-A2 represents an anionic bidentate ligand. nH1 represents an integer of 0 to 5, nH2 represents an integer of 1 to 10, ArH1 has formula (H1-1), LH1 represents an alkylene or arylene group, and ArH2 represents an aromatic heterocyclic group. Ring RH1 and ring RH2 each represent a monocyclic or fused-ring aromatic heterocyclic ring, and XH1 represents a single bond.
    Type: Application
    Filed: March 7, 2017
    Publication date: July 9, 2020
    Applicant: Sumitomo Chemical Company, Limited
    Inventors: Toshiaki SASADA, Daisuke FUKUSHIMA, Shin-ya TANAKA
  • Publication number: 20200216481
    Abstract: Tetradentate platinum complexes comprising an imidazole/benzimidazole carbene having a structure of Formula I is disclosed. In Formula I, M is Pd or Pt. These platinum carbenes with the specific substituents disclosed herein are novel and provides phosphorescent emissive compounds that exhibit physical properties that can be tuned, such as sublimation temperature, emission color, and device stability.
    Type: Application
    Filed: March 3, 2020
    Publication date: July 9, 2020
    Applicant: Universal Display Corporation
    Inventors: Hsiao-Fan Chen, Tyler Fleetham, Peter Wolohan, Jason Brooks, Pierre-Luc T. Boudreault, Charles J. Stanton, III, Olexandr Tretyak, Raghupathi Neelarapu, Katarina Rohlfing, Douglas Williams
  • Publication number: 20200216482
    Abstract: A cyclopentadienyl nickel complex compound represented by a formula (I): Ni(R1nC5H5-n)2 (I), where R1 is each independently a C1-4 alkyl group, and n is 2, 3, or 4.
    Type: Application
    Filed: March 16, 2020
    Publication date: July 9, 2020
    Inventors: Yasuo Fujii, Shigeo Yasuhara
  • Publication number: 20200216483
    Abstract: The present invention relates to an SMB-based fucose separation method and an apparatus therefor and, more particularly, to a method and an apparatus for continuously separating fucose from a microalgae-derived monosaccharide mixture or a multi-component mixture (monosaccharide substances, amino acid substances, and glycerol components) using an SMB process.
    Type: Application
    Filed: April 16, 2018
    Publication date: July 9, 2020
    Inventors: Yong Keun CHANG, Sungyong MUN, Seokbin HONG, Jae-hwan CHOI
  • Publication number: 20200216484
    Abstract: A purification agent which includes a compound having a betaine structure, and which is for a sugar chain having a length equal to or longer than that of a monosaccharide or for a glycopeptide having a sugar chain having a length equal to or longer than that of a monosaccharide.
    Type: Application
    Filed: October 31, 2018
    Publication date: July 9, 2020
    Applicant: SUMITOMO BAKELITE CO., LTD.
    Inventors: Masaaki Toyoda, Takayuki Matsumoto, Midori Sakaguchi, Takahiro Katayama
  • Publication number: 20200216485
    Abstract: Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI. Also provided herein are pharmaceutical compositions comprising such conjugates. Further provided herein are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-glycoprotein conjugate.
    Type: Application
    Filed: September 24, 2019
    Publication date: July 9, 2020
    Inventors: Luis Z. AVILA, Clark Q. PAN, Patrick FINN, John HARRAHY, Qun ZHOU, Yunxiang ZHU, Paul A. KONOWICZ, Duncan E. PATERSON, Andreas PEER, Joseph P. KUTZKO, Michael R. REARDON, James E. STEFANO, Xiaoyang ZHENG, Robert J. MILLER, Lauren YOUNG
  • Publication number: 20200216486
    Abstract: Described herein are markers, conjugates, compositions and methods for hypoxia imaging, mapping, and therapy. A compound comprising bio-reductively activated (BA) arm, linker arm and a mapping click wherein BA contains one for more of substituted or unsubstituted 2/4/5-substituted nitroimidazoles, or substituted benzotriazene-1,4-dioxides, or substituted 1,2,3/1,2,4-triazoles, or substituted 1,4-benzoquinones, or a combination of two homo-or hetero BA moieties, wherein linker arm contains C1-16 alkane, alkene, alkyne, alicyclic or aromatic linkers with or without hetero atoms as in ethers, amine, esters, acid, amides, 5 and 6 membered sugar sings with the substitution as described above, both monosaccharides and disaccharides, wherein mapping click contains one of substituted or unsubstituted —N3-, CN, SCN, substituted alkynes for click chemistry.
    Type: Application
    Filed: September 19, 2018
    Publication date: July 9, 2020
    Inventors: Piyush KUMAR, Hassan ELSAIDI, Leonard Irving WIEBE, Michael WEINFELD
  • Publication number: 20200216487
    Abstract: The invention provides a process for the preparation of nicotinamide mononucleotide having formula (I): The method involves the protection of nicotinamide riboside by ketalization, followed by phosphorylation and then deprotection to provide nicotinamide mononucleotide.
    Type: Application
    Filed: March 16, 2020
    Publication date: July 9, 2020
    Applicant: Cornell University
    Inventors: Anthony Sauve, Farheen Sultana Yang Mohammed
  • Publication number: 20200216488
    Abstract: The present invention provides a modified nucleic acid monomer compound having a specific backbone such as 2-ethylglycerol or methoxymethyl-1,3-propanediol backbone instead of a ribose or deoxyribose backbone of a nucleoside, and an oligonucleic acid analogue containing the monomer compound as at least one of building blocks. The oligonucleic acid analogue containing the nucleic acid monomer compound of the present invention allows provision of an oligonucleic acid analogue having excellent biological stability and/or target gene silencing activity.
    Type: Application
    Filed: June 14, 2018
    Publication date: July 9, 2020
    Applicant: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Yoshinori Takahashi, Yuta Suzuki